ABSTRACT
PURPOSE: The aim of this study was to assess the efficacy and safety of tamsulosin, 0.2mg/day on sexual function in Korean BPH patients. Patients and Methods: 116 patients (mean age: 60 yrs) with BPH were enrolled in this study and 0.2mg of tamsulosin was administrated every night for 3 months. Primary efficacy was evaluated with changes of IIEF and GEQ. Secondary efficacy parameters were changes of IPSS and QoL, uroflowmetry, changes of total IIEF and IIEF domain score according to the severity of IPSS, and retrograde ejaculation. RESULTS: Before treatment, patients of moderate IPSS (8-19) and severe IPSS (20-35) were 56% and 44% and QoL3 were 33.6% and 66.4%. In primary efficacy evaluation, total IIEF score was significantly increased from 37.0+/- 18.2 to 40.5+/- 18.9 (p<0.01). All domains of IIEF except orgasmic function were significantly improved. GEQ showed improvement of erection in 34.4% and intercourse ability in 30.1%. In secondary efficacy evaluation, IPSS was significantly decreased from 18.4+/- 6.9 to 12.9+/- 6.7 (p<0.01) and QoL was significantly improved from 3.8+/- 1.1 to 2.7+/- 1.4 (p<0.01). Qmax significantly increased from 14.2+/- 8.3 to 16.5+/- 11.3 ml/sec (p<0.01). Total IIEF score and EF domain score were significantly improved from 36.8+/- 18.5 to 41.8+/- 19.1 (p<0.01) and from 13.0+/- 7.1 to 14.7+/- 7.9 (p<0.01) in patients of moderate IPSS but no improvement in severe patients. Retrograde ejaculation occurred in 2 patients (2%). No serious adverse reactions were observed. CONCLUSIONS: Tamsulosin, 0.2mg/day was effective and safe dose for the improvement of LUTS and sexual function for Korean BPH/LUTS patients.
Subject(s)
Humans , Male , Ejaculation , Orgasm , Prospective Studies , SulfonamidesABSTRACT
Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. The evidence from results showing that testosterone decrease progressively with age and that a significant percentage of men over the age 60 years have serum testosterone levels that are below the lower limits of young adults(age 20~30) men suggest that older hypogonadal men will benefit from testosterone replacement therapy. Long term data on the effects of testosterone replacement therapy in the older population, however, are limited and specific risk data on the prostate and cardiovascular systems are needed. Key questions of functional benefits that may retard frailty of the elderly are not yet available. The recommendations described below were based on document suggested by the International Society of Andrology(ISA), the International Society for the Study of the Aging Male(ISSAM) and the European Association of Urology(EAU) in 2005. The academic committee of the Korean Society for the Aging Male Research(KOSAR) suggested these recommendations to provide the appropriate information about investigation, treatment and monitoring for late-onset hypogonadism in aging Korean men following an annual meeting in October 2006.